MSFT   183.67 (-0.91%)
FB   227.45 (-1.18%)
GOOGL   1,420.61 (-1.30%)
AMZN   2,473.94 (-0.18%)
NVDA   352.69 (+0.54%)
CGC   16.63 (+0.36%)
BABA   219.10 (+0.22%)
MU   51.17 (+4.60%)
GE   7.48 (+1.49%)
TSLA   881.46 (-0.17%)
AMD   52.61 (-0.23%)
T   31.59 (+0.25%)
ACB   14.15 (-1.05%)
F   6.34 (+2.42%)
DIS   124.17 (+1.62%)
BAC   26.30 (+1.19%)
MSFT   183.67 (-0.91%)
FB   227.45 (-1.18%)
GOOGL   1,420.61 (-1.30%)
AMZN   2,473.94 (-0.18%)
NVDA   352.69 (+0.54%)
CGC   16.63 (+0.36%)
BABA   219.10 (+0.22%)
MU   51.17 (+4.60%)
GE   7.48 (+1.49%)
TSLA   881.46 (-0.17%)
AMD   52.61 (-0.23%)
T   31.59 (+0.25%)
ACB   14.15 (-1.05%)
F   6.34 (+2.42%)
DIS   124.17 (+1.62%)
BAC   26.30 (+1.19%)
MSFT   183.67 (-0.91%)
FB   227.45 (-1.18%)
GOOGL   1,420.61 (-1.30%)
AMZN   2,473.94 (-0.18%)
NVDA   352.69 (+0.54%)
CGC   16.63 (+0.36%)
BABA   219.10 (+0.22%)
MU   51.17 (+4.60%)
GE   7.48 (+1.49%)
TSLA   881.46 (-0.17%)
AMD   52.61 (-0.23%)
T   31.59 (+0.25%)
ACB   14.15 (-1.05%)
F   6.34 (+2.42%)
DIS   124.17 (+1.62%)
BAC   26.30 (+1.19%)
MSFT   183.67 (-0.91%)
FB   227.45 (-1.18%)
GOOGL   1,420.61 (-1.30%)
AMZN   2,473.94 (-0.18%)
NVDA   352.69 (+0.54%)
CGC   16.63 (+0.36%)
BABA   219.10 (+0.22%)
MU   51.17 (+4.60%)
GE   7.48 (+1.49%)
TSLA   881.46 (-0.17%)
AMD   52.61 (-0.23%)
T   31.59 (+0.25%)
ACB   14.15 (-1.05%)
F   6.34 (+2.42%)
DIS   124.17 (+1.62%)
BAC   26.30 (+1.19%)
Log in

NASDAQ:GNPXGenprex Stock Price, Forecast & News

$3.15
+0.33 (+11.70 %)
(As of 06/4/2020 12:11 PM ET)
Add
Compare
Today's Range
$2.77
Now: $3.15
$3.30
50-Day Range
$1.99
MA: $2.70
$3.54
52-Week Range
$0.23
Now: $3.15
$7.03
Volume5.00 million shs
Average Volume1.29 million shs
Market Capitalization$103.48 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.9
Genprex, Inc. operates as a clinical-stage gene therapy company. It engages in developing a new approach for treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells, and modulates the immune response against cancer cells. Genprex, Inc. was founded in 2009 and is headquartered in Austin, Texas.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.31 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GNPX
CUSIPN/A
Phone512-370-4081

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.15 per share

Profitability

Net Income$-10,650,000.00

Miscellaneous

EmployeesN/A
Market Cap$103.48 million
Next Earnings Date8/11/2020 (Estimated)
OptionableNot Optionable

Receive GNPX News and Ratings via Email

Sign-up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter.

Genprex (NASDAQ:GNPX) Frequently Asked Questions

How has Genprex's stock been impacted by COVID-19 (Coronavirus)?

Genprex's stock was trading at $2.42 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, GNPX stock has increased by 30.2% and is now trading at $3.15. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Genprex?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genprex in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Genprex.

When is Genprex's next earnings date?

Genprex is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Genprex.

How were Genprex's earnings last quarter?

Genprex Inc (NASDAQ:GNPX) issued its earnings results on Thursday, May, 14th. The company reported ($0.20) EPS for the quarter. View Genprex's earnings history.

What price target have analysts set for GNPX?

2 brokerages have issued 1-year price objectives for Genprex's shares. Their forecasts range from $5.00 to $5.00. On average, they anticipate Genprex's share price to reach $5.00 in the next year. This suggests a possible upside of 58.7% from the stock's current price. View analysts' price targets for Genprex.

Has Genprex been receiving favorable news coverage?

News stories about GNPX stock have been trending very negative on Thursday, InfoTrie reports. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Genprex earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next few days. View the latest news aboutGenprex.

Who are some of Genprex's key competitors?

What other stocks do shareholders of Genprex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genprex investors own include Inovio Pharmaceuticals (INO), Opko Health (OPK), Tonix Pharmaceuticals (TNXP), Co-Diagnostics (CODX), Ibio (IBIO), SCYNEXIS (SCYX), Onconova Therapeutics (ONTX), VBI Vaccines (VBIV), FuelCell Energy (FCEL) and vTv Therapeutics (VTVT).

Who are Genprex's key executives?

Genprex's management team includes the following people:
  • Mr. John Rodney Varner, Co-Founder, CEO, Sec. & Chairman (Age 62)
  • Dr. Julien L. Pham M.P.H., M.D., MPH, Pres & COO (Age 42)
  • Mr. Ryan M. Confer, Chief Financial Officer (Age 37)
  • Dr. Jack A. Roth FACS, M.D., Chairman of Scientific & Medical Advisory Board

What is Genprex's stock symbol?

Genprex trades on the NASDAQ under the ticker symbol "GNPX."

Who are Genprex's major shareholders?

Genprex's stock is owned by a number of institutional and retail investors. Top institutional investors include Advisor Group Holdings Inc. (0.20%), IHT Wealth Management LLC (0.13%), Bank of New York Mellon Corp (0.08%), Frontier Wealth Management LLC (0.05%), Mid Atlantic Financial Management Inc. ADV (0.05%) and Jane Street Group LLC (0.03%). Company insiders that own Genprex stock include John Rodney Varner and Julien L Pham. View institutional ownership trends for Genprex.

Which major investors are buying Genprex stock?

GNPX stock was purchased by a variety of institutional investors in the last quarter, including Advisor Group Holdings Inc., IHT Wealth Management LLC, Bank of New York Mellon Corp, Frontier Wealth Management LLC, Mid Atlantic Financial Management Inc. ADV, and Jane Street Group LLC. Company insiders that have bought Genprex stock in the last two years include John Rodney Varner, and Julien L Pham. View insider buying and selling activity for Genprex.

How do I buy shares of Genprex?

Shares of GNPX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Genprex's stock price today?

One share of GNPX stock can currently be purchased for approximately $3.15.

How big of a company is Genprex?

Genprex has a market capitalization of $103.48 million.

What is Genprex's official website?

The official website for Genprex is www.genprex.com.

How can I contact Genprex?

Genprex's mailing address is 1601 Trinity Street Suite 3.322, AUSTIN TX, 78712. The company can be reached via phone at 512-370-4081 or via email at [email protected]

This page was last updated on 6/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.